0001104659-22-067697.txt : 20220602 0001104659-22-067697.hdr.sgml : 20220602 20220602170105 ACCESSION NUMBER: 0001104659-22-067697 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220602 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220602 DATE AS OF CHANGE: 20220602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001023024 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 582301143 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31812 FILM NUMBER: 22991719 BUSINESS ADDRESS: STREET 1: 210 MAIN STREET WEST CITY: BAUDETTE STATE: MN ZIP: 56623 BUSINESS PHONE: 2186343500 MAIL ADDRESS: STREET 1: 210 MAIN STREET WEST CITY: BAUDETTE STATE: MN ZIP: 56623 FORMER COMPANY: FORMER CONFORMED NAME: BIOSANTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19991228 FORMER COMPANY: FORMER CONFORMED NAME: BEN ABRAHAM TECHNOLOGIES INC DATE OF NAME CHANGE: 19991027 8-K 1 tm2217581d1_8k.htm FORM 8-K
0001023024 false 0001023024 2022-06-02 2022-06-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported): June 2, 2022

 

ANI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-31812 58-2301143
(State or other jurisdiction
of incorporation)		 (Commission File Number) (I.R.S. Employer
Identification Number)

 

210 Main Street West

Baudette, Minnesota

   56623
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (218) 634-3500

 

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:
Common Stock   ANIP   Nasdaq Stock Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

  

 

 

Item 2.05 COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES

 

On June 2, 2022, ANI Pharmaceuticals, Inc. (the “Company”) announced its decision to cease operations at its manufacturing plant located in Oakville, Ontario, Canada as part of ongoing initiatives to capture operational synergies following the Company’s acquisition of Novitium Pharma.

 

The Oakville manufacturing plant is expected to cease operations by the first quarter of 2023. The Company is unable at this time to make a good faith estimate of the amount of charges and costs that may be incurred in connection with this closure. In accordance with Item 2.05 of Form 8-K, the Company will timely file an amendment to this report upon the determination of such estimates.

 

ITEM 7.01REGULATION FD DISCLOSURE

 

On June 2, 2022, the Company issued a press release announcing that it will cease operations at its Oakville, Ontario, Canada manufacturing plant. The press release is furnished as Exhibit 99.1 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

No.   Description
99.1   Press release, dated June 2, 2022, issued by ANI
     
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANI PHARMACEUTICALS, INC.
   
  By: /s/ Stephen P. Carey
    Stephen P. Carey
    Senior Vice President, Finance and Chief Financial Officer
Dated: June 2, 2022  

 

 

 

 EX-99.1 2 tm2217581d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

FOR IMMEDIATE RELEASE

 

ANI Pharmaceuticals Announces Consolidation of Manufacturing
Network, Capturing Operational Synergies Post Novitium Acquisition

 

-- Operations at Oakville, Canada manufacturing plant expected to end by
first quarter 2023 --

 

-- Action part of ongoing efforts to drive cost-competitiveness and deliver sustainable
growth for generics business --

 

-- Preliminary estimate of $7 million to $8 million improvement in profitability and cash
flow on annualized basis --

 

-- Manufacturing network well positioned to ensure new product launches and supply
continuity for patients and customers --

 

BAUDETTE, Minn.--(BUSINESS WIRE) – June 2, 2022 – ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it intends to cease operations at its Oakville, Ontario, Canada manufacturing plant by first quarter 2023. This action is part of ongoing initiatives to capture operational synergies following the Company’s acquisition of Novitium Pharma in November 2021.

 

ANI remains committed to meeting patient needs and ensuring the continuity of supply of its medicines to patients and customers. The Company will transition the majority of products manufactured or packaged in Oakville to one of its three U.S.-based manufacturing sites. The Company is seeking to find potential buyers for the Oakville site and remains committed to treating employees with fairness and respect.

 

“Driving cost-competitiveness and efficiencies is imperative for achieving sustainable growth in the U.S. generics industry. Consolidation of our manufacturing network allows ANI to achieve significant cost savings and stay competitive. Our remaining manufacturing sites are well-placed to support our future growth and enable us to continue serving patients in need,” said Nikhil Lalwani, President and CEO of ANI. 

 

ANI expects this action to improve profitability and cash flow by $7 million to $8 million on an annualized basis. The Company is in the process of developing best estimates of expected charges related to acceleration of depreciation, asset impairments, and employee severance and benefit expense and will provide updates when that information is available.

 

About ANI

 

ANI Pharmaceuticals is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit www.anipharmaceuticals.com.

 

 

 

 

 

Forward-Looking Statements

 

To the extent any statements made in this release relate to information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding when the Company will complete the closure of the Oakville plant, statements regarding the financial impact of ceasing operations at the Oakville plant, statements about the Company’s corporate strategy, future operations, products, financial performance, financial position, operating results and prospects, including plans for sustainable growth, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates.

 

Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the costs involved in commercializing Cortrophin Gel; the ability to maintain regulatory approval of the product and maintain sufficiency of the product; the ability to obtain reimbursement from third-party payors for this product; evolving government legislation; risks the Company may face with respect to importing raw materials; the use of single source suppliers and the time it may take to validate and qualify another supplier, if necessary; whether the Company experiences disruptions to its operations resulting from the plant closure; manufacturing difficulties or delays; ANI’s reliance on third parties over which it may not always have full control; increased competition and strategies employed by competitors; the ability to realize benefits anticipated from acquisitions, including, but not limited to, post-close integration activities related to the Novitium Pharma acquisition; costs and regulatory requirements relating to contract manufacturing arrangements; delays or failure in obtaining product approvals from the U.S. Food and Drug Administration; general business and economic conditions, including the ongoing impact of and uncertainties regarding the COVID-19 pandemic; market trends for our products; regulatory environment and changes; and regulatory and other approvals relating to product development and manufacturing, and other risks and uncertainties that are described in ANI’s Annual Report on Form 10-K, quarterly reports on Form 10-Q, and other periodic reports filed with the Securities and Exchange Commission.

 

More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

 

 

  

Investor Contact

 

Lisa M. Wilson

In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com

 

Media Contact:

Angela Salerno-Robin
dna Communications
T: 212-445-8219
E: ASalerno-Robin@dna-comms.com

 

SOURCE: ANI Pharmaceuticals, Inc.

 

 

 

 EX-101.SCH 3 anip-20220602.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 anip-20220602_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 anip-20220602_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2217581d1_ex99-1img001.jpg GRAPHIC begin 644 tm2217581d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
Jun. 02, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 02, 2022
Entity File Number 001-31812
Entity Registrant Name ANI PHARMACEUTICALS, INC.
Entity Central Index Key 0001023024
Entity Tax Identification Number 58-2301143
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 210 Main Street West
Entity Address, City or Town Baudette
Entity Address, State or Province MN
Entity Address, Postal Zip Code 56623
City Area Code 218
Local Phone Number 634-3500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ANIP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

XML 8 tm2217581d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001023024 2022-06-02 2022-06-02 iso4217:USD shares iso4217:USD shares 0001023024 false 8-K 2022-06-02 ANI PHARMACEUTICALS, INC. DE 001-31812 58-2301143 210 Main Street West Baudette MN 56623 218 634-3500 Common Stock ANIP NASDAQ false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://anipharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2217581d1_8k.htm anip-20220602.xsd anip-20220602_lab.xml anip-20220602_pre.xml tm2217581d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2217581d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2217581d1_8k.htm" ] }, "labelLink": { "local": [ "anip-20220602_lab.xml" ] }, "presentationLink": { "local": [ "anip-20220602_pre.xml" ] }, "schema": { "local": [ "anip-20220602.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "anip", "nsuri": "http://anipharmaceuticals.com/20220602", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2217581d1_8k.htm", "contextRef": "From2022-06-02to2022-06-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://anipharmaceuticals.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2217581d1_8k.htm", "contextRef": "From2022-06-02to2022-06-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-067697-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-067697-xbrl.zip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end